Prime MedicinePRME
PRME
About: Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Employees: 214
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
3.03% less ownership
Funds ownership: 49.05% [Q4 2024] → 46.02% (-3.03%) [Q1 2025]
5% less funds holding
Funds holding: 130 [Q4 2024] → 123 (-7) [Q1 2025]
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
36% less capital invested
Capital invested by funds: $188M [Q4 2024] → $120M (-$67.6M) [Q1 2025]
49% less call options, than puts
Call options by funds: $120K | Put options by funds: $237K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
62%
downside
Avg. target
$6.50
66%
upside
High target
$12
206%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Citigroup Samantha Semenkow | 62%downside $1.50 | Neutral Downgraded | 27 May 2025 |
JMP Securities Silvan Tuerkcan | 53%upside $6 | Market Outperform Maintained | 20 May 2025 |
Chardan Capital Geulah Livshits | 206%upside $12 | Buy Maintained | 19 May 2025 |
Financial journalist opinion
Based on 7 articles about PRME published over the past 30 days
Neutral
GlobeNewsWire
10 hours ago
Prime Medicine Announces Pricing of Public Offering
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share.
Neutral
GlobeNewsWire
16 hours ago
Prime Medicine Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Positive
Zacks Investment Research
21 hours ago
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Prime Medicine, Inc. (PRME) could be a good stock pick from a technical perspective. PRME recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Neutral
Zacks Investment Research
21 hours ago
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
An updated edition of the June 27, 2025, article.
Neutral
Business Wire
2 weeks ago
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy
BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy for people with cystic fibrosis (CF). Prime Medicine uses a gene editing technology called prime editing — a technology that enables a wide range of modifications to the DNA with a high degree of precision. The company — founded by Drs. David Liu and Andrew Anzalone, who pioneered the development of.
Neutral
GlobeNewsWire
2 weeks ago
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot Prime Editors may benefit more than 93% of people with CF -- CAMBRIDGE, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $24 million in additional funding to accelerate the development of Prime Editors designed to permanently correct cystic fibrosis-related lung disease.
Positive
Seeking Alpha
3 weeks ago
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications
Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds, but is pivoting to larger in-vivo gene editing liver disease targeting opportunities. PRME is prioritizing in-vivo gene editing therapy programs targeting Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with IND filings expected in H1 and mid-2026, respectively. These new programs use in-vivo LNP delivery, target larger markets, and could provide substantially better advantages for PRME over ex-vivo gene editing.
Neutral
GlobeNewsWire
2 months ago
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 5, 2025, at 10:30 a.m.
Neutral
GlobeNewsWire
2 months ago
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
Neutral
GlobeNewsWire
2 months ago
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
Charts implemented using Lightweight Charts™